

**16-NOV-2018 6:10
CANCER CONTROL ACCRUAL REPORT**

06:10 Friday, November 16, 2018 1

STUDY	O R P E E G N	ARM	TOTAL	REGS.	REGS.	REGS.	REGS.	REGS.	ADMIN
			REGS.	LAST 12 Month	LAST 6 Month	LAST 3 Month	LAST 30 DAYS	LAST 7 DAYS	
S1007-Breast,Adj,N1,Endocrine+/-Chemo	1 Y 1	Recurrence Score testing	9383	0	0	0	0	0	BREAST
			9383	0	0	0	0	0	
	2 Y 2	Chemo and Endocrine Therapy	2547	0	0	0	0	0	
		3 Endocrine Therapy Alone	2536	0	0	0	0	0	
			5083	0	0	0	0	0	
S1207-Brst,Adj,Endocrine+/-Everolimus	1 Y 1	Blinded drug + Endocrine	878	175	82	46	13	2	BREAST
		2 Blinded drug + Endocrine	886	176	83	44	21	5	
			1764	351	165	90	34	7	
S1316-Compar. Effectiv. Trial for MBO	1 Y 1	Randomization Surgery	7	3	2	2	0	0	SURV
		2 Randomization Non-surgical M	7	4	2	1	1	1	
		3 Patient Choice Surgery	54	17	9	7	4	1	
		4 Patient Choice Non-surgical M	100	20	0	0	0	0	
			168	44	13	10	5	2	
S1415CD-TrACER CSF Standing Order Intervention for FN	1 Y 1	Site assigned to Cohort	594	253	116	56	22	2	CCD
		2 Site randomized: Control	417	199	101	50	21	6	
		3 SiteRand Int Risk: CSF	726	433	171	82	35	2	
		4 SiteRand Int Risk: No CSF	579	358	168	87	26	2	
			2316	1243	556	275	104	12	
S1417CD-Colorectal, Cost Cohort Study	1 Y 1	Observation	336	205	89	44	12	1	CCD
			336	205	89	44	12	1	
S1418-Breast, Adj, TNBC, MK-3475 (Pembrolizumab)	1 Y 1	Tissue for PD-L1 testing	359	250	136	67	30	7	BREAST
			359	250	136	67	30	7	
	2 Y 2	Observation	149	100	53	25	9	0	
		3 MK-3475 (Pembrolizumab)	149	106	58	29	9	2	
			298	206	111	54	18	2	
S1501-Surv, Breast Stg IV, Card Tox w/ Carvedilol	1 Y 0	Screening	55	53	45	29	8	2	SURV
			55	53	45	29	8	2	
	2 Y 1	Carvedilol	10	9	8	4	2	0	
		2 No prophylaxis	11	11	8	6	4	0	
		3 Observation	27	27	24	14	1	1	

**16-NOV-2018 6:10
CANCER CONTROL ACCRUAL REPORT**

STUDY	O R P E E G N	ARM	TOTAL	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	REGS. LAST	ADMIN
			REGS.	Month	Month	Month	DAYS	DAYS	
			48	47	40	24	7	1	
S1602-Blad, HG NMIBC, TICE/Tokyo/Prime+Tokyo BCG	1	Y 1	TICE BCG	61	44	25	16	3	1 GU
		2	Tokyo-172 BCG	61	45	28	16	4	1
		3	Prime + Tokyo-172 BCG	60	43	26	15	6	0
				182	132	79	47	13	2
S1703-Met Breast, STM-monitoring v Usual Care	1	Y 0	Screening	6	6	6	6	2	0 CCD
				6	6	6	6	2	0
	2	Y 2	Intervention (STMDDM)	1	1	1	1	1	1
				1	1	1	1	1	1
S1802-Pros, Stg IV, SST +/- Surg/RT to Primary Tum	1	Y 0	Induction SST	16	16	16	16	9	1 GU
				16	16	16	16	9	1
	2	Y 1	Standard Systemic Therapy Only	3	3	3	3	2	0
		2	SST + Surgery/RT	3	3	3	3	2	1
				6	6	6	6	4	1
S0820-PACES: ColrecStg0-3 Blind DFMO/Sulindac	0	Y 0	Pre-Registration	505	80	16	7	3	1 PREV
				505	80	16	7	3	1
	1	Y 1	Blinded drug	73	28	13	6	2	0
		2	Blinded drug	36	0	0	0	0	0
		3	Blinded drug	35	0	0	0	0	0
		4	Blinded drug	74	26	12	4	0	0
				218	54	25	10	2	0